Kymera Therapeutics

Kymera Therapeutics to Present Interim Results from a Non-Interventional Study Characterizing IRAK4 Expression and Demonstrating Proof of Mechanism of an IRAK4 Degrader in Patients with Hidradenitis Suppurativa

Data to be presented at the 5th Annual Symposium on Hidradenitis Suppurativa Advances (SHSA) Results support clinical development of IRAK4-targeted protein degrader in hidradenitis suppurativa (HS) and other IL-1R/TLR-driven autoimmune and inflammatory diseases , with Phase 1 trial on track for